Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Future pharmaceutical industries | UNKNOWN |
Not provided
Not provided
Not provided
The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients who failed previous therapies.
This will be randomized, parallel group, comparative open-label study that will be conducted to evaluate the efficacy and tolerability of a four-drug regimen (modified LOAD regimen) in eradicating HP. The study will evaluate the efficacy of modified LOAD regimens(levofloxacin/moxifloxacin, nitazoxanide, doxycycline and lansoprazole) inpatients who failed previous therapies and compare these regimens with the classic triple therapy (amoxicillin, clarithromycin and lansoprazole) in treatment naïve patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Naïve patients - ACO therapy | Active Comparator | One hundred patients naive to H. Pylori eradication therapy will receive ACO therapy for 14 days (amoxicillin 1 g with breakfast and dinner, clarithromycin 500 mg with breakfast and dinner and lansoprazole 40 mg twice daily before meals). |
|
| Naïve patients - LNDL therapy | Experimental | One hundred patients naive to H. Pylori eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals) |
|
| Naïve patients - MNDL therapy | Experimental | One hundred patients naive to H. Pylori eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals) |
|
| Treatment-experienced patients- LNDL therapy | Experimental | One hundred patients who were unresponsive to previous eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Naïve patients - ACO therapy | Drug | Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with negative results of enzyme immunoassay H. pylori antigen test in stool (Monocent, Inc., CA, USA). | successful eradication of H. pylori confirmed by H. pylori antigen test in stool. Monocent, Inc.'s H. pylori Antigen Test System is an enzyme immunoassay for the qualitative and quantitative detection of H. pylori antigen in human stool. The patient has to be asked to collect the specimen avoiding any possible contact with urine or water. The patient submitted to the test should not be under antibiotic or anti-acid treatments. immunoassay for the qualitative and quantitative detection of H. li tiihtlIt iitdd id ithiy fthqlitti pylori antigen in human stool. diif iblHli | 4 weeks after completion of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by Egyptian pharmacovigilance Center (EPVC) criteria | Safety and tolerability of these regimens will be assessed by reporting adverse events by Individual Case Safety Reports for EPVC | Through study completion, an average of 24 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gasser I El-Azab, M.D. | Contact | 01280250026 | g.elazab@gmail.com | |
| Sherif Abdel-Salam, M.D. | Contact | 01063319696 | sherif.abdelbaky@med.tanta.edu.eg |
| Name | Affiliation | Role |
|---|---|---|
| Gasser El-Azab, M.D. | National Liver Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Liver institute - Menoufia University | Recruiting | Shibīn al Kawm | Menoufia | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42151286 | Derived | El-Azab G, Salam SA, Moustafa E, Abuoelhassan A, Shamseya A, Ellakany A, Abdelaal U, Assem M, Khalil F, Mahmoud A, Elsabaawy M, Hussein B, Ezz-Eldin M, Hassany S, Zaghloul N, Magdy M. Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study. Sci Rep. 2026 May 18;16(1):15337. doi: 10.1038/s41598-026-51062-4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Treatment-experienced patients- MNDL therapy | Experimental | One hundred patients who were unresponsive to previous eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals) |
|
| Naïve patients - LNDL therapy | Drug | Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days |
|
| Naïve patients - MNDL therapy | Drug | Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days |
|
| Treatment-experienced patients- LNDL therapy | Drug | Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days |
|
| Treatment-experienced patients- MNDL therapy | Drug | Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days |
|